Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug Zepbound, can now meet present and projected national demand, the FDA said in a statement.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

A federal judge has sided with the FDA over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine and the Mounjaro diabetes treatment — from a shortages list ...

The level of weight loss was similar to that achieved over the same period with Novo Nordisk’s injection but slightly lower than that with Eli Lilly’s injection in unrelated trials.

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...

Eli Lilly's recent Phase III results for its oral weight loss pill have demonstrated remarkable results. LLY has emerged as the frontrunner to tap into the next stage of growth through ...

Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients; The company hopes the new discount, which caps monthly out-of-pocket ...

All doses of Eli Lilly’s weight loss drugs Zepbound and Mounjaro are available in the United States after more than a year of being in shortage, according to the Food and Drug Administration’s ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...

And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion.